|
2006
ANNUAL Topic INDEX
[ Topic | Author ]
Adolescent gynecology
Guiding adolescent contraceptive choices. Jun:35-39
The young woman’s initial gynecologic visit. Sep:25-29
back to top
Alternative & complementary medicine
Botulinum toxin in the treatment of neurogenic and idiopathic urinary
incontinence. May:14-18,23-24,44
Nutraceuticals and arthritis: weighing the evidence. Jul:14-18,39
Soy consumption and cholesterol levels. Aug:31-33
back to top
Amenorrhea
Evaluating amenorrhea. Jun:40-46
Missing the missing uterus. Jun:19-24
What you should know about your period. Jun:49-50
back to top
Breast symptoms
Evaluation and management of common breast complaints. Oct:28-38
back to top
Cancer
Cervical adenocarcinoma and endometrial biopsy-site hematoma. Jan:34-36
Cervical cancer: a vaccine-preventable malignancy. Oct:9-10
Clinical uses of aromatase inhibitors: beyond breast cancer. Oct:50,55-58
The health benefits of hormonal contraception. Jan(RA suppl):10-12
Health benefits of hormonal contraception. Apr(suppl):5-9
Health benefits of hormonal contraception. Apr(RA suppl):6-9(in
Spanish:6-9)
Hypereosinophilic syndrome associated with cervical squamous cell
carcinoma. Feb:32-34
Noncontraceptive health benefits of hormonal contraception. Oct:42,44,75
Ovarian cancer: it’s time to act. Nov:10-11
Primary care for female cancer survivors. Feb:27-31
The role of aromatase inhibitors in breast cancer therapy. Jan:23-32
Smoking and nonrespiratory cancers in women. Sep:53-58
Tuberculous peritonitis mimicking ovarian cancer. Sep:48-52
back to top
Cardiovascular complications/disorders
HELLP syndrome: diagnosis, management, and long-term outcome. Sep:59-64
Metabolic effects of antipsychotic medications. Nov:46-50,55-56
Practical issues in the management of dyslipidemia in women. Feb:42-46
Preoperative cardiac and pulmonary evaluation and risk reduction:
a brief review. Aug:15-21,40
Soy consumption and cholesterol levels. Aug:31-33
Thrombophilia and adverse maternal-perinatal outcomes. Jul:42-48
back to top
Compliance
The compliance conundrum. May:11-12
The noncompliant patient. May:28-31
back to top
Congenital anomalies
Evaluating amenorrhea. Jun:40-46
Missing the missing uterus. Jun:19-24
Thrombophilia and adverse maternal-perinatal outcomes. Jul:42-48
back to top
Continuing medical education (CME)
Anemia in pregnancy: an update. Oct:60-64 [test 65-66]
Bacterial vaginosis: diagnosis and therapy. Aug:41-46 [test 47-48]
Clinical implications and complications of undiagnosed HSV. Mar(CE
suppl):6-10 [test 23-24]
Diagnosis and management of HSV: challenge of maximizing therapy.
Mar(CE suppl):11-16 [test 23-24]
Endometriosis, part 1: clinical diagnosis and analgesia. Nov:62-68
[test 69-70]
Endometriosis, part 2: surgery for symptom relief and infertility.
Dec:54-58 [test 59-60]
Evaluating amenorrhea. Jun:40-46 [test 47-48]
The evolution of contraception: from potions to progestins. Oct(CE
suppl):3-4 [test 31-32]
Genital herpes: highly stigmatized, underdiagnosed, and unrecognized.
Mar(CE suppl):17-22 [test 23-24]
HELLP syndrome: diagnosis, management, and long-term outcome. Sep:59-64
[test 65-66]
Hysteroscopic myomectomy: a review. Jan:37-42 [test 43-44]
Insertion and removal of the single-rod contraceptive implant. Oct(CE
suppl):26-30 [test 31-32]
Maximizing progestin-only contraceptive success: the two-way street
of counseling. Oct(CE suppl):11-14 [test 31-32]
A new contraceptive implant. Oct(CE suppl):19-25 [test 31-32]
Nonoral progestin-only methods of contraception. Oct(CE suppl):5-10
[test 31-32]
Postpartum depression, part 1: prevalence and considerations in screening.
Mar:37-42 [test 43-44]
Postpartum depression, part 2: office interventions. Apr:48-52 [test
53-54
Practical issues in the management of dyslipidemia in women. Feb:42-46
[test 47-48]
Thrombophilia and adverse maternal-perinatal outcomes. Jul:42-48
[test 49-50]
Tip of the iceberg: the startling incidence and prevalence of HSV-2.
Mar(CE suppl):3-5 [test 23-24]
Uterine artery embolization for symptomatic leiomyomata. May:45-50
[test 51-52]
back to top
Contraception and contraceptives
Altering the hormone-free interval with extended-cycle contraception.
Sep(suppl):1-4
Birth control doesn’t work if you don’t use it. Jan(RA
suppl):2-4
Birth control: know all of your options. Jan(RA suppl):1
Conclusion: finding the right contraceptive for each patient. Apr(suppl):27-28
Contraception counseling. Apr(suppl):21-23
Contraception: individual patients, individual choices. Apr(suppl):24-28
Contraceptive use: effectiveness and continuation. Apr(RA suppl):4-5(in
Spanish 4-5)
Contraceptives can help manage abnormal menstrual bleeding. Apr(RA
suppl):10-11,18(in Spanish:10-11,18)
Depot medroxyprogesterone acetate, skeletal health, and adolescent
girls: implications of the black-box warning. Apr:36-38
Elimination and alteration of the hormone-free interval: reasons
and methods. Nov(suppl):1-8
Endometriosis, part 1: clinical diagnosis and analgesia. Nov:62-68
The evolution of contraception: from potions to progestins. Oct(CE
suppl):3-4
Guiding adolescent contraceptive choices. Jun:35-39
The health benefits of hormonal contraception. Jan(RA suppl):10-12
Health benefits of hormonal contraception. Apr(suppl):5-9
Health benefits of hormonal contraception. Apr(RA suppl):6-9(in
Spanish:6-9)
Hormonal contraception: new alternatives to the pill. Jan(RA suppl):5-7
How birth control changes your vaginal ecosystem. Jan(RA suppl):13-16
How to talk to your provider. Apr(RA suppl):19-20(in Spanish:19-20)
Increasing use of emergency contraception. Dec:44-45
Insertion and removal of the single-rod contraceptive implant. Oct(CE
suppl):26-30
Intrauterine device perforation. Aug:34-37
Introduction: finding the right contraceptive for each patient.
Apr(suppl):3-4
Is menstruation necessary? Nov:43-44
Lifestyle considerations for contraception choices. Apr(RA suppl):15-18(in
Spanish:15-18)
Maximizing progestin-only contraceptive success: the two-way street
of counseling. Oct(CE suppl):11-14
A new contraceptive implant. Oct(CE suppl):19-25
Noncontraceptive health benefits of hormonal contraception. Oct:42,44,75
Nonoral progestin-only methods of contraception. Oct(CE suppl):5-10
Over-the-counter emergency contraception. Oct:47-48
Placenta accreta requiring hysterectomy following endometrial ablation.
Apr:21-22,26
Reproductive health and sexually transmitted infections in lesbian
women. Aug:38-40
Sterilization versus regret. Apr(RA suppl):12-14(in Spanish:12-14)
Suppressing menstruation with extended hormonal contraception. Feb:38-40
Talking to your clinician about contraception. Jan(RA suppl):8-9
Tubal sterilization: a review of the advantages and disadvantages.
Apr(suppl):17-20
What is hormonal contraception? Oct(CE suppl):15-16(in Spanish:17-18)
What you should know about contraception. Apr(suppl):13-16
What you should know about your period. Jun:49-50
back to top
Counseling
Conclusion: finding the right contraceptive for each patient. Apr(suppl):27-28
Contraception counseling. Apr(suppl):21-23
Genital herpes: highly stigmatized, underdiagnosed, and unrecognized.
Mar(CE suppl):17-22
Guiding adolescent contraceptive choices. Jun:35-39
Managing postmenopausal dyspareunia: beyond hormone therapy. Nov:24-30
Maximizing progestin-only contraceptive success: the two-way street
of counseling. Oct(CE suppl):11-14
Noncontraceptive health benefits of hormonal contraception. Oct:42,44,75
Placenta accreta requiring hysterectomy following endometrial ablation.
Apr:21-22,26
Smoking and nonrespiratory cancers in women. Sep:53-58
back to top
Dermatologic conditions
The health benefits of hormonal contraception. Jan(RA suppl):10-12
Health benefits of hormonal contraception. Apr(suppl):5-9
Health benefits of hormonal contraception. Apr(RA suppl):6-9(in
Spanish:6-9)
Optimizing bone health in women with systemic lupus erythematosus.
Feb:19-23
back to top
Diabetes
Metabolic effects of antipsychotic medications. Nov:46-50,55-56
back to top
Diagnostic guidelines/tools
Bacterial vaginosis: diagnosis and therapy. Aug:41-46
Diagnosis and management of HSV: challenge of maximizing therapy.
Mar(CE suppl):11-16 HELLP syndrome: diagnosis, management, and long-term
outcome. Sep:59-64
Managing abnormal uterine bleeding. Apr(suppl):10-12,23
Overview of vaginitis: office-based DNA testing. Aug insert
A practical guide to thyroid disease in women. Jan:11-21
Second-trimester genetic ultrasonography. Mar:32-36,49
What’s new in osteoporosis management. Oct:26-27,75
back to top
Editorials
Cervical cancer: a vaccine-preventable malignancy. Oct:9-10
The compliance conundrum. May:11-12
The culture of misinformation: an adverse influence on the health
care of women. Jun:8,13
Don’t “just” do your job. Mar:8-9
Firsts. Feb:10-11
The green coats are coming! The green coats are coming! Apr:9-10
Ovarian cancer: it’s time to act. Nov:10-11
Partnering to achieve a diverse and healthy geographic region.
Sep:10-11
The practice of evidence-based medicine. Jul:10,13
Transvaginal reconstructive mesh: the evidence is lacking… Dec:11-12
Video games, sports, and the art of surgery. Aug:13-14
back to top
Endocrinologic disorders
A practical guide to thyroid disease in women. Jan:11-21
Thyroid disease: a primer for the care of midlife women. Dec:39-43
back to top
Evidence-based medicine/approaches
The culture of misinformation: an adverse influence on the health
care of women. Jun:8,13
The practice of evidence-based medicine. Jul:10,13
back to top
Genetics
Evaluating amenorrhea. Jun:40-46
Missing the missing uterus. Jun:19-24
Second-trimester genetic ultrasonography. Mar:32-36,49
Trimethylaminuria: a noninfectious cause of vaginal odor. Mar:10-15,49.
back to top
Gynecologic disorders
Clinical uses of aromatase inhibitors: beyond breast cancer. Oct:50,55-58
Endometriosis, part 1: clinical diagnosis and analgesia. Nov:62-68
Endometriosis, part 2: surgery for symptom relief and infertility.
Dec:54-58
Evaluating amenorrhea. Jun:40-46
Evaluation and management of common breast complaints. Oct:28-38
Health benefits of hormonal contraception. Apr(RA suppl):6-9(in
Spanish:6-9)
Hysteroscopic myomectomy: a review. Jan:37-42
Managing abnormal uterine bleeding. Apr(suppl):10-12,23
Managing postmenopausal dyspareunia: beyond hormone therapy. Nov:24-30
Noncontraceptive health benefits of hormonal contraception. Oct:42,44,75
Premyomectomy uterine fibroid embolization for massive uterine enlargement.
Dec:33-35
Septic pelvic thrombophlebitis: an update. Nov:35-40
Transvaginal reconstructive mesh: the evidence is lacking… Dec:11-12
Uterine artery embolization complicated by nontarget labial embolization.
May:26-27
Uterine artery embolization for symptomatic leiomyomata. May:45-50
Vaginal atrophy. Sep:gatefold
Vaginal estrogen therapy: the question of systemic absorption. Feb:24-26
back to top
Hair growth patterns
Postmenopausal hair growth patterns. Jun:29-30
back to top
Headache
Health benefits of hormonal contraception. Apr(suppl):5-9
Health benefits of hormonal contraception. Apr(RA suppl):6-9(in
Spanish:6-9)
Migraine: principles of treatment. Sep:16-20
back to top
Hematologic disorders
Anemia in pregnancy: an update. Oct:60-64
HELLP syndrome: diagnosis, management, and long-term outcome. Sep:59-64
The hematologist, the gynecologist, and the patient with menorrhagia:
may the circle be unbroken. Feb:35-37
Hereditary thrombophilia and thrombocythemia in pregnancy. Jul:35-39
Hypereosinophilic syndrome associated with cervical squamous cell
carcinoma. Feb:32-34
Thrombophilia and adverse maternal-perinatal outcomes. Jul:42-48
back to top
Hormones and hormone
therapy
Altering the hormone-free interval with extended-cycle contraception.
Sep(suppl):1-4
The clinical significance of ?8,9-dehydroestrone sulfate in treating
menopausal vasomotor symptoms. Apr(Clinical Perspectives suppl):1-8
Clinical uses of aromatase inhibitors: beyond breast cancer. Oct:50,55-58
Elimination and alteration of the hormone-free interval: reasons
and methods. Nov(suppl):1-8
Evaluating amenorrhea. Jun:40-46
Health benefits of hormonal contraception. Apr(suppl):5-9
The impact of the Women’s Health Initiative on the perimenopausal
patient. Dec:46-53
Managing abnormal uterine bleeding. Apr(suppl):10-12,23
Managing postmenopausal dyspareunia: beyond hormone therapy. Nov:24-30
Nonoral progestin-only methods of contraception. Oct(CE suppl):5-10
Postmenopausal hair growth patterns. Jun:29-30
Suppressing menstruation with extended hormonal contraception.
Feb:38-40
Testosterone therapy in postmenopausal women. Apr:29-31
Vaginal atrophy. Sep:gatefold
Vaginal estrogen therapy: the question of systemic absorption.
Feb:24-26
What you should know about your period. Jun:49-50
What’s new in osteoporosis management. Oct:26-27,75
back to top
Infections
Bacterial vaginosis: diagnosis and therapy. Aug:41-46
How birth control changes your vaginal ecosystem. Jan(RA suppl):13-16
Overview of vaginitis: office-based DNA testing. Aug insert
Trimethylaminuria: a noninfectious cause of vaginal odor. Mar:10-15,49.
Tuberculous peritonitis mimicking ovarian cancer. Sep:48-52
back to top
Infertility
Clinical uses of aromatase inhibitors: beyond breast cancer. Oct:50,55-58
Endometriosis, part 2: surgery for symptom relief and infertility.
Dec:54-58
The health benefits of hormonal contraception. Jan(RA suppl):10-12
back to top
Inflammatory disorders
Optimizing bone health in women with systemic lupus erythematosus.
Feb:19-23
back to top
Laparoscopy
Endometriosis, part 2: surgery for symptom relief and infertility.
Dec:54-58
Intrauterine device perforation. Aug:34-37
Laparoscopic management of ovarian ectopic pregnancy. Mar:16-20
Robotics: the next step in the evolution of minimally invasive
gynecologic surgery. Oct:14-19
Tuberculous peritonitis mimicking ovarian cancer. Sep:48-52
back to top
Laparotomy
Cervical adenocarcinoma and endometrial biopsy-site hematoma. Jan:34-36
Robotics: the next step in the evolution of minimally invasive
gynecologic surgery. Oct:14-19
Tuberculous peritonitis mimicking ovarian cancer. Sep:48-52
back to top
Liability
Communication and the dissatisfied patient, part 1. Dec:28-30
An ounce of prevention: axioms to consider when entering practice.
Sep:30-33
back to top
Medical coding
Bacterial vaginosis: diagnosis and therapy. Aug:41-46
Endometriosis, part 1: clinical diagnosis and analgesia. Nov:62-68
Evaluating amenorrhea. Jun:40-46
Evaluation and management of common breast complaints. Oct:28-38
Intrapartum management of the growth-restricted fetus. Feb:12-15
Migraine: principles of treatment. Sep:16-20
Overview of vaginitis: office-based DNA testing. Aug insert
Postpartum depression, part 1: prevalence and considerations in
screening. Mar:37-42
A practical guide to thyroid disease in women. Jan:11-21
Screening newborns for inherited metabolic disease. Dec:18-27
Thrombophilia and adverse maternal-perinatal outcomes. Jul:42-48
Uterine artery embolization for symptomatic leiomyomata. May:45-50
back to top
Menopause
The clinical significance of ?8,9-dehydroestrone sulfate in treating
menopausal vasomotor symptoms. Apr(Clinical Perspectives suppl):1-8
Clinical uses of aromatase inhibitors: beyond breast cancer. Oct:50,55-58
Health benefits of hormonal contraception. Apr(RA suppl):6-9(in
Spanish:6-9)
The impact of the Women’s Health Initiative on the perimenopausal
patient. Dec:46-53
Managing postmenopausal dyspareunia: beyond hormone therapy. Nov:24-30
Noncontraceptive health benefits of hormonal contraception. Oct:42,44,75
Optimizing bone health in women with systemic lupus erythematosus.
Feb:19-23
Postmenopausal hair growth patterns. Jun:29-30
The role of aromatase inhibitors in breast cancer therapy. Jan:23-32
Soy consumption and cholesterol levels. Aug:31-33
Testosterone therapy in postmenopausal women. Apr:29-31
Thyroid disease: a primer for the care of midlife women. Dec:39-43
Vaginal atrophy. Sep:gatefold
Vaginal estrogen therapy: the question of systemic absorption.
Feb:24-26
What’s new in osteoporosis management. Oct:26-27,75
back to top
Menorrhagia
Contraceptives can help manage abnormal menstrual bleeding. Apr(RA
suppl):10-11,18(in Spanish:10-11,18)
Health benefits of hormonal contraception. Apr(suppl):5-9
The hematologist, the gynecologist, and the patient with menorrhagia:
may the circle be unbroken. Feb:35-37
Managing abnormal uterine bleeding. Apr(suppl):10-12,23
Noncontraceptive health benefits of hormonal contraception. Oct:42,44,75
What you should know about your period. Jun:49-50
back to top
Menstruation
Altering the hormone-free interval with extended-cycle contraception.
Sep(suppl):1-4
Contraceptives can help manage abnormal menstrual bleeding. Apr(RA
suppl):10-11,18(in Spanish:10-11,18)
Elimination and alteration of the hormone-free interval: reasons
and methods. Nov(suppl):1-8
Evaluating amenorrhea. Jun:40-46
The health benefits of hormonal contraception. Jan(RA suppl):10-12
Health benefits of hormonal contraception. Apr(suppl):5-9
Health benefits of hormonal contraception. Apr(RA suppl):6-9(in
Spanish:6-9)
Is menstruation necessary? Nov:43-44
Missing the missing uterus. Jun:19-24
Noncontraceptive health benefits of hormonal contraception. Oct:42,44,75
Suppressing menstruation with extended hormonal contraception.
Feb:38-40
What you should know about your period. Jun:49-50
back to top
Metabolic disorders
Screening newborns for inherited metabolic disease. Dec:18-27
Trimethylaminuria: a noninfectious cause of vaginal odor. Mar:10-15,49.
back to top
Neonatal care
Screening newborns for inherited metabolic disease. Dec:18-27
back to top
Nutrition
Dietary guidelines for Americans. Sep:34-40
back to top
Obstetrics and gynecology
Cervical cancer: a vaccine-preventable malignancy. Oct:9-10
Communication and the dissatisfied patient, part 1. Dec:28-30
The compliance conundrum. May:11-12
The culture of misinformation: an adverse influence on the health
care of women. Jun:8,13
The green coats are coming! The green coats are coming! Apr:9-10
Home delivery for patients at low risk. Dec:36-38
My most memorable moment: death, despair, destruction, and a new
beginning. Oct:20,25
My most memorable moment: Murphy’s law of obstetrics. Jul:33-34
My most memorable moment: precious. Mar:31
My most memorable moment: a privilege, not a burden. Dec:13
My most memorable moment: reminding us of our purpose. Sep:23-24
My most memorable moment: special delivery, military style. Nov:22-23
My most memorable moment: a wealth of experience. Apr:32,35
My most memorable moment: winter headaches. May:32
An ounce of prevention: axioms to consider when entering practice.
Sep:30-33
Ovarian cancer: it’s time to act. Nov:10-11
Partnering to achieve a diverse and healthy geographic region.
Sep:10-11
Robotics: the next step in the evolution of minimally invasive
gynecologic surgery. Oct:14-19
Septic pelvic thrombophlebitis: an update. Nov:35-40
Should we offer elective primary cesarean delivery? Sep:45-46
Tuberculous peritonitis mimicking ovarian cancer. Sep:48-52
Understanding the basics of risk management. Jun:25-27
back to top
Osteoporosis/Bone health
Bone strength: a multifactorial view. Apr:12-14
The clinical significance of ?8,9-dehydroestrone sulfate in treating
menopausal vasomotor symptoms. Apr(Clinical Perspectives suppl):1-8
Depot medroxyprogesterone acetate, skeletal health, and adolescent
girls: implications of the black-box warning. Apr:36-38
Optimizing bone health in women with systemic lupus erythematosus.
Feb:19-23
Persistence with medication in women using daily versus weekly
bisphosphonates. Mar:21-28
Smoking and nonrespiratory cancers in women. Sep:53-58
What’s new in osteoporosis management. Oct:26-27,75
back to top
Patient education
Bladder evaluation diary. Mar(RA suppl):13(in Spanish:14)
Contraceptive use: effectiveness and continuation. Apr(RA suppl):4-5(in
Spanish 4-5)
Contraceptives can help manage abnormal menstrual bleeding. Apr(RA
suppl):10-11,18(in Spanish:10-11,18)
Dietary guidelines for Americans. Sep:34-40
Evaluation and treatment. [interstitial cystitis/painful bladder
syndrome] Mar(RA suppl):8-9(in Spanish:10-11)
Frequently asked questions about hormone therapy. Apr(Clinical
Perspectives suppl):7
Guiding adolescent contraceptive choices. Jun:35-39
Health benefits of hormonal contraception. Apr(RA suppl):6-9(in
Spanish:6-9)
How to talk to your provider. Apr(RA suppl):19-20(in Spanish:19-20)
Increasing use of emergency contraception. Dec:44-45
Interstitial cystitis/painful bladder syndrome checklist. Mar(RA
suppl):14
Lifestyle considerations for contraception choices. Apr(RA suppl):15-18(in
Spanish:15-18)
Maintaining quality of life: a testimonial. [interstitial cystitis/painful
bladder syndrome] Mar(RA suppl):11-12(in Spanish:12-13)
The noncompliant patient. May:28-31
Overlapping symptoms. [interstitial cystitis/painful bladder syndrome]
Mar(RA suppl):5-7,10(in Spanish:6-9)
Pelvic pain and urgency/frequency patient symptom scale. Mar(RA
suppl):15(in Spanish:15)
Smoking and nonrespiratory cancers in women. Sep:53-58
Sterilization versus regret. Apr(RA suppl):12-14(in Spanish:12-14)
What is hormonal contraception? Oct(CE suppl):15-16(in Spanish:17-18)
What is painful bladder syndrome? Mar(RA suppl):2-4,10(in Spanish:2-5)
What
you should know about… (also in Spanish)
Aromatase inhibitors. Jan:45-46
Bacterial vaginosis. Aug:49-50
Contraception. Apr(suppl):13-16
Emergency contraception. Dec:61-62
Endometriosis. Nov:71-72
Extended-cycle contraception. Feb:49-50
Hormone therapy. Apr:55-56
Nutraceuticals. Jul:51-52
Nutrition in pregnancy. Oct:67-68
Postpartum depression. Mar:45-46
Uterine fibroids. May:53-54
Vaginal atrophy. Sep:67-68
Your period. Jun:49-50
back to top
Pharmacotherapy
Anxiety disorders in women, part 2: pharmacotherapy. Aug:23-28
Cervical cancer: a vaccine-preventable malignancy. Oct:9-10
The clinical significance of ?8,9-dehydroestrone sulfate in treating
menopausal vasomotor symptoms. Apr(Clinical Perspectives suppl):1-8
Clinical uses of aromatase inhibitors: beyond breast cancer. Oct:50,55-58
Diagnosis and management of HSV: challenge of maximizing therapy.
Mar(CE suppl):11-16 Endometriosis, part 1: clinical diagnosis and
analgesia. Nov:62-68
Evaluation and management of common breast complaints. Oct:28-38
HELLP syndrome: diagnosis, management, and long-term outcome. Sep:59-64
Hereditary thrombophilia and thrombocythemia in pregnancy. Jul:35-39
Managing abnormal uterine bleeding. Apr(suppl):10-12,23
Metabolic effects of antipsychotic medications. Nov:46-50,55-56
Migraine: principles of treatment. Sep:16-20
The noncompliant patient. May:28-31
Optimizing bone health in women with systemic lupus erythematosus.
Feb:19-23
Persistence with medication in women using daily versus weekly
bisphosphonates. Mar:21-28
Postpartum depression, part 2: office interventions. Apr:48-52
Practical issues in the management of dyslipidemia in women. Feb:42-46
Preoperative cardiac and pulmonary evaluation and risk reduction:
a brief review. Aug:15-21,40
The role of aromatase inhibitors in breast cancer therapy. Jan:23-32
Thyroid disease: a primer for the care of midlife women. Dec:39-43
Uterine artery embolization complicated by nontarget labial embolization.
May:26-27
What is painful bladder syndrome? Mar(RA suppl):2-4,10(in Spanish:2-5)
What’s new in osteoporosis management. Oct:26-27,75
back to top
Pregnancy
Anemia in pregnancy: an update. Oct:60-64
Anxiety disorders in women, part 2: pharmacotherapy. Aug:23-28
Bacterial vaginosis: diagnosis and therapy. Aug:41-46
HELLP syndrome: diagnosis, management, and long-term outcome. Sep:59-64
Hereditary thrombophilia and thrombocythemia in pregnancy. Jul:35-39
Intrapartum management of the growth-restricted fetus. Feb:12-15
Laparoscopic management of ovarian ectopic pregnancy. Mar:16-20
Placenta accreta requiring hysterectomy following endometrial ablation.
Apr:21-22,26
Thrombophilia and adverse maternal-perinatal outcomes. Jul:42-48
back to top
Preventive strategies
Cervical cancer: a vaccine-preventable malignancy. Oct:9-10
Migraine: principles of treatment. Sep:16-20
The role of aromatase inhibitors in breast cancer therapy. Jan:23-32
Smoking and nonrespiratory cancers in women. Sep:53-58
The United States Preventive Services Task Force: putting recommendations
into practice. May:34-38,42-44
back to top
Psychiatric disorders
Anxiety disorders in women, part 1: prevalence, trends, and psychotherapy.
Jul:20,25-27
Anxiety disorders in women, part 2: pharmacotherapy. Aug:23-28
Metabolic effects of antipsychotic medications. Nov:46-50,55-56
Postpartum depression, part 1: prevalence and considerations in
screening. Mar:37-42
Postpartum depression, part 2: office interventions. Apr:48-52
back to top
Psychosocial issues
Clinical implications and complications of undiagnosed HSV. Mar(CE
suppl):6-10
Genital herpes: highly stigmatized, underdiagnosed, and unrecognized.
Mar(CE suppl):17-22
Managing postmenopausal dyspareunia: beyond hormone therapy. Nov:24-30
back to top
Psychotherapy
Anxiety disorders in women, part 1: prevalence, trends, and psychotherapy.
Jul:20,25-27
back to top
Pulmonary complications/disorders
Preoperative cardiac and pulmonary evaluation and risk reduction:
a brief review. Aug:15-21,40
back to top
Regulatory/Reform issues
Understanding the basics of risk management. Jun:25-27
back to top
Rheumatic disorders
Nutraceuticals and arthritis: weighing the evidence. Jul:14-18,39
Optimizing bone health in women with systemic lupus erythematosus.
Feb:19-23
back to top
Risk management
Understanding the basics of risk management. Jun:25-27
back to top
Screening/Guidelines
Evaluating amenorrhea. Jun:40-46
Evaluation and management of common breast complaints. Oct:28-38
Managing postmenopausal dyspareunia: beyond hormone therapy. Nov:24-30
The noncompliant patient. May:28-31
Postpartum depression, part 1: prevalence and considerations in
screening. Mar:37-42
Postpartum depression, part 2: office interventions. Apr:48-52
A practical guide to thyroid disease in women. Jan:11-21
Practical issues in the management of dyslipidemia in women. Feb:42-46
Preoperative cardiac and pulmonary evaluation and risk reduction:
a brief review. Aug:15-21,40
Primary care for female cancer survivors. Feb:27-31
Screening newborns for inherited metabolic disease. Dec:18-27
Second-trimester genetic ultrasonography. Mar:32-36,49
The United States Preventive Services Task Force: putting recommendations
into practice. May:34-38,42-44
What is painful bladder syndrome? Mar(RA suppl):2-4,10(in Spanish:2-5)
The young woman’s initial gynecologic visit. Sep:25-29
back to top
Sexual health
Clinical implications and complications of undiagnosed HSV. Mar(CE
suppl):6-10
Genital herpes: highly stigmatized, underdiagnosed, and unrecognized.
Mar(CE suppl):17-22
Guiding adolescent contraceptive choices. Jun:35-39
Managing postmenopausal dyspareunia: beyond hormone therapy. Nov:24-30
Testosterone therapy in postmenopausal women. Apr:29-31
back to top
Sexually transmitted infections (STIs)
Cervical cancer: a vaccine-preventable malignancy. Oct:9-10
Clinical implications and complications of undiagnosed HSV. Mar(CE
suppl):6-10
Diagnosis and management of HSV: challenge of maximizing therapy.
Mar(CE suppl):11-16
Genital herpes: highly stigmatized, underdiagnosed, and unrecognized.
Mar(CE suppl):17-22
The health benefits of hormonal contraception. Jan(RA suppl):10-12
Overview of vaginitis: office-based DNA testing. Aug insert
Reproductive health and sexually transmitted infections in lesbian
women. Aug:38-40
Tip of the iceberg: the startling incidence and prevalence of HSV-2.
Mar(CE suppl):3-5
back to top
Surgery
Bacterial vaginosis: diagnosis and therapy. Aug:41-46
Cervical adenocarcinoma and endometrial biopsy-site hematoma. Jan:34-36
Endometriosis, part 2: surgery for symptom relief and infertility.
Dec:54-58
Hysteroscopic myomectomy: a review. Jan:37-42
Management of rectal prolapse in elderly women: a study. Nov:58-61
Midurethral slings: ins, outs, ups, downs. Apr:40-47
Placenta accreta requiring hysterectomy following endometrial ablation.
Apr:21-22,26
Premyomectomy uterine fibroid embolization for massive uterine
enlargement. Dec:33-35
Preoperative cardiac and pulmonary evaluation and risk reduction:
a brief review. Aug:15-21,40
Robotics: the next step in the evolution of minimally invasive
gynecologic surgery. Oct:14-19
Should we offer elective primary cesarean delivery? Sep:45-46
Sterilization versus regret. Apr(RA suppl):12-14(in Spanish:12-14)
Transvaginal reconstructive mesh: the evidence is lacking… Dec:11-12
Tubal sterilization: a review of the advantages and disadvantages.
Apr(suppl):17-20
Video games, sports, and the art of surgery. Aug:13-14
back to top
Ultrasonography
Cervical adenocarcinoma and endometrial biopsy-site hematoma. Jan:34-36
Laparoscopic management of ovarian ectopic pregnancy. Mar:16-20
Second-trimester genetic ultrasonography. Mar:32-36,49
back to top
Urogynecologic disorders
Evaluating amenorrhea. Jun:40-46
Evaluation and treatment. [interstitial cystitis/painful bladder
syndrome] Mar(RA suppl):8-9(in Spanish:10-11)
Maintaining quality of life: a testimonial. [interstitial cystitis/painful
bladder syndrome] Mar(RA suppl):11-12(in Spanish:12-13)
Missing the missing uterus. Jun:19-24
Overlapping symptoms. [interstitial cystitis/painful bladder syndrome]
Mar(RA suppl):5-7,10(in Spanish:6-9)
What is painful bladder syndrome? Mar(RA suppl):2-4,10(in Spanish:2-5)
back to top
Urologic disorders
Botulinum toxin in the treatment of neurogenic and idiopathic urinary
incontinence. May:14-18,23-24,44
Evaluation and treatment. [interstitial cystitis/painful bladder
syndrome] Mar(RA suppl):8-9(in Spanish:10-11)
Maintaining quality of life: a testimonial. [interstitial cystitis/painful
bladder syndrome] Mar(RA suppl):11-12(in Spanish:12-13)
Management of rectal prolapse in elderly women: a study. Nov:58-61
Midurethral slings: ins, outs, ups, downs. Apr:40-47
Overlapping symptoms. [interstitial cystitis/painful bladder syndrome]
Mar(RA suppl):5-7,10(in Spanish:6-9)
What is painful bladder syndrome? Mar(RA suppl):2-4,10(in Spanish:2-5)
back to top
|
